Reactions Weekly

, Volume 1695, Issue 1, pp 139–139 | Cite as

Dacarbazine/interferon beta/nivolumab

Acquired drug resistance during treatment of melanoma: case report
Case report


  1. Han N, et al. Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma. Inflammation and Regeneration 38: No. 3, 05 Mar 2018. Available from: URL: - Japan

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations